Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 14.04 as of 2026-09-12T00:15:13.746Z.
Consensus retrieved: 2026-09-10T23:32:57.315Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-09-12T00:15:13.746Z.
Quote observation: 2026-09-11T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 19cd922b1f9625d6df659bf0613b6337c5f71d5174687a3b1e11508267bc93ab
Forward PE Ratio (14.04) = Dated Quote Price ($177.85) / Consensus Forward EPS ($12.67)
FORWARD PE RATIO
14.04
SECTOR MEDIAN · HEALTHCARE
18.95
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
-25.93%
vs the sector median at left
Becton, Dickinson and Company
Market Cap
$49.00B
Forward PE Ratio
14.04
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Becton, Dickinson and Company (BDX) | $49.00B | 14.04 |
| Humana Inc. (HUM)vs › | $49.21B | 44.77 |
| Edwards Lifesciences Corporation (EW)vs › | $48.58B | 28.11 |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $43.20B | 18.72 |
| IQVIA Holdings Inc. (IQV)vs › | $43.09B | 20.19 |
| Cardinal Health, Inc. (CAH)vs › | $54.94B | 18.70 |
| Agilent Technologies, Inc. (A)vs › | $41.50B | 23.69 |
| Moderna, Inc. (MRNA)vs › | $57.13B | N/A |
| IDEXX Laboratories, Inc. (IDXX)vs › | $39.81B | 34.17 |
| Cencora, Inc. (COR)vs › | $62.57B | 17.99 |
Trailing P/E
53.6
reported TTM EPS
Forward P/E
14.0
consensus EPS · fiscal year ending 2026-09-30
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $12.67 implies +281.6% EPS growth vs the reported trailing $3.32.
At the dated quote price of $177.85, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-09-30 | $12.67 | $12.08 – $12.76 | 8 | 14.0x |
| 2027-09-30 | $13.29 | $13.10 – $13.80 | 8 | 13.4x |
| 2028-09-30 | $14.17 | $11.86 – $16.49 | 2 | 12.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
